Skewed epigenetics: An alternative therapeutic option for diabetes complications

Journal of Diabetes Research

Volumn 2015, Issue , 2015, Pages

  Togliatto, Gabriele ^a   Dentelli, Patrizia ^a   Brizzi, Maria Felice ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CURCUMIN; METFORMIN; MICRORNA; NUCLEIC ACID; REACTIVE SULFUR SPECIES; RESVERATROL;

CHROMATIN; CYTOPLASM; DIABETES MELLITUS; DIABETIC PATIENT; DNA METHYLATION; EPIGENETICS; FINGER DERMATOGLYPHICS; GENE CONTROL; HIGH RISK PATIENT; HISTONE MODIFICATION; HUMAN; NUCLEAR REPROGRAMMING; PRIORITY JOURNAL; REVIEW; CHROMATIN ASSEMBLY AND DISASSEMBLY; DIABETIC ANGIOPATHIES; GENETIC EPIGENESIS; GENETICS; HYPERGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS;

CHROMATIN ASSEMBLY AND DISASSEMBLY; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; EPIGENESIS, GENETIC; HUMANS; HYPERGLYCEMIA;

EID: 84929378553     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2015/373708     Document Type: Review

References (84)

1. S. Wild, G. Roglic, A. Green, R. Sicree, and H. King, "Global prevalence of diabetes: estimates for the year 2000 and projections for 2030", Diabetes Care, vol. 27, no. 5, pp. 1047-1053, 2004.
2. American Diabetes Association, "Diagnosis and classification of diabetes mellitus", Diabetes Care, vol. 35, pp. S64-S71, 2012.
3. A. H. Mokdad, E. S. Ford, B. A. Bowman et al., "Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001", Journal of the American Medical Association, vol. 289, no. 1, pp. 76-79, 2003.
4. P. Hossain, B. Kawar, and M. El Nahas, "Obesity and diabetes in the developing world-a growing challenge", The New England Journal of Medicine, vol. 356, no. 3, pp. 213-215, 2007.
5. M. Gili, A. Orsello, S. Gallo, and M. F. Brizzi, "Diabetesassociated macrovascular complications: cell-based therapy a new tool?" Endocrine, vol. 44, no. 3, pp. 557-575, 2012.
6. A. Trombetta, G. Togliatto, A. Rosso et al., "Increase of palmitic acid concentration impairs endothelial progenitor cell and bone marrow-derived progenitor cell bioavailability: role of the STAT5/PPARγ transcriptional complex", Diabetes, vol. 62, no. 4, pp. 1245-1257, 2013.
7. M. F. Brizzi, P. Dentelli, M. Pavan et al., "Diabetic LDL inhibits cell-cycle progression via STAT5B and p21waf", Journal of Clinical Investigation, vol. 109, no. 1, pp. 111-119, 2002.
8. F. Paneni, S. Costantino, and F. Cosentino, "Molecular mechanisms of vascular dysfunction and cardiovascular biomarkers in type 2 diabetes", Cardiovascular Diagnosis and Therapy, vol. 4, no. 4, pp. 324-332, 2014.
9. "The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group", The New England Journal of Medicine, vol. 329, pp. 977-986, 1993.
10. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group, "Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study", Journal of the American Medical Association, vol. 290, no. 16, pp. 2159-2167, 2003.
11. R. Turner, "Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group", The Lancet, vol. 352, no. 9131, pp. 837-853, 1998.
12. R. R. Holman, S. K. Paul, M. A. Bethel, D. R. Matthews, and H. A. W. Neil, "10-Year follow-up of intensive glucose control in type 2 diabetes", The New England Journal of Medicine, vol. 359, no. 15, pp. 1577-1589, 2008.
13. A. Ceriello, "Hypothesis: the 'metabolic memory', the new challenge of diabetes", Diabetes Research and Clinical Practice, vol. 86, supplement 1, pp. S2-S6, 2009.
14. M. E. Cooper and A. El-Osta, "Epigenetics: mechanisms and implications for diabetic complications", Circulation Research, vol. 107, no. 12, pp. 1403-1413, 2010.
15. M. A. Reddy and R. Natarajan, "Epigenetic mechanisms in diabetic vascular complications", Cardiovascular Research, vol. 90, no. 3, pp. 421-429, 2011.
16. F. Paneni, M. Volpe, T. F. Lüscher, and F. Cosentino, "SIRT1, p6shc, and set7/9 in vascular hyperglycemic memory: bringing all the strands together", Diabetes, vol. 62, no. 6, pp. 1800-1807, 2013.
17. G. Togliatto, A. Trombetta, P. Dentelli, A. Rosso, and M. F. Brizzi, "MIR221/MIR222-driven post-transcriptional regulation of P27KIP1 and P57KIP2 is crucial for high-glucose- and AGE-mediated vascular cell damage", Diabetologia, vol. 54, no. 7, pp. 1930-1940, 2011.
18. F. Giacco and M. Brownlee, "Oxidative stress and diabetic complications", Circulation Research, vol. 107, no. 9, pp. 1058-1070, 2010.
19. T. Nishikawa, D. Edelstein, X. L. Du et al., "Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage", Nature, vol. 404, no. 6779, pp. 787-790, 2000.
20. S. Kiritoshi, T. Nishikawa, K. Sonoda et al., "Reactive oxygen species from mitochondria induce cyclooxygenase-2 gene expression in human mesangial cells: potential role in diabetic nephropathy", Diabetes, vol. 52, no. 10, pp. 2570-2577, 2003.
21. M. T. Coughlan, D. R. Torburn, S. A. Penfold et al., "Rageinduced cytosolic ROS promote mitochondrial superoxide generation in diabetes", Journal of the American Society of Nephrology, vol. 20, no. 4, pp. 742-752, 2009.
22. A. El-Osta, D. Brasacchio, D. Yao et al., "Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia", The Journal of Experimental Medicine, vol. 205, pp. 2409-2417, 2008.
23. J. Okabe, C. Orlowski, A. Balcerczyk et al., "Distinguishing hyperglycemic changes by set7 in vascular endothelial cells", Circulation Research, vol. 110, no. 8, pp. 1067-1076, 2012.
24. S. P. Gray, E. Di Marco, J. Okabe et al., "NADPH oxidase 1 plays a key role in diabetes mellitus-accelerated atherosclerosis", Circulation, vol. 127, no. 18, pp. 1888-1902, 2013.
25. F. Paneni, P. Mocharla, A. Akhmedov et al., "Gene silencing of the mitochondrial adaptor p66shc suppresses vascular hyperglycemic memory in diabetes", Circulation Research, vol. 111, no. 3, pp. 278-289, 2012.
26. S. Roy, R. Sala, E. Cagliero, and M. Lorenzi, "Overexpression of fbronectin induced by diabetes or high glucose: phenomenon with a memory", Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 1, pp. 404-408, 1990.
27. L. Pirola, A. Balcerczyk, J. Okabe, and A. El-Osta, "Epigenetic phenomena linked to diabetic complications", Nature Reviews Endocrinology, vol. 6, no. 12, pp. 665-675, 2010.
28. F. Paneni, S. Costantino, M. Volpe, T. F. Lüscher, and F. Cosentino, "Epigenetic signatures and vascular risk in type 2 diabetes: a clinical perspective", Atherosclerosis, vol. 230, no. 2, pp. 191-197, 2013.
29. A. Bird, "DNA methylation patterns and epigenetic memory", Genes and Development, vol. 16, no. 1, pp. 6-21, 2002.
30. D. P. Bartel, "MicroRNAs: genomics, biogenesis, mechanism, and function", Cell, vol. 116, no. 2, pp. 281-297, 2004.
31. R. B. Meagher and K. J. Müssar, "The influence of DNA sequence on epigenome-induced pathologies", Epigenetics & Chromatin, vol. 5, no. 1, article 11, 2012.
32. M. Wegner, D. Neddermann, M. Piorunska-Stolzmann, and P. P. Jagodzinski, "Role of epigenetic mechanisms in the development of chronic complications of diabetes", Diabetes Research and Clinical Practice, vol. 105, pp. 164-175, 2014.
33. P. Mathiyalagan, S. T. Keating, X. Du, and A. El-Osta, "Chromatin modifications remodel cardiac gene expression", Cardiovascular Research, vol. 103, no. 1, pp. 7-16, 2014.
34. D. Brasacchio, J. Okabe, C. Tikellis et al., "Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail", Diabetes, vol. 58, no. 5, pp. 1229-1236, 2009.
35. S. Zhou, H.-Z. Chen, Y.-Z. Wan et al., "Repression of P66Shc expression by SIRT1 contributes to the prevention of hyperglycemia-induced endothelial dysfunction", Circulation Research, vol. 109, no. 6, pp. 639-648, 2011.
36. C.-S. Kim, S.-B. Jung, A. Naqvi et al., "P53 impairs endotheliumdependent vasomotor function through transcriptional upregulation of P66shc", Circulation Research, vol. 103, no. 12, pp. 1441-1450, 2008.
37. Z. Zheng, H. Chen, J. Li et al., "Sirtuin 1-mediated cellular metabolic memory of high glucose via the LKB1/AMPK/ROS pathway and therapeutic effects of metformin", Diabetes, vol. 61, no. 1, pp. 217-228, 2012.
38. S. K. T. Ooi and T. H. Bestor, "The colorful history of active DNA demethylation", Cell, vol. 133, no. 7, pp. 1145-1148, 2008.
39. C. P. Walsh and T. H. Bestor, "Cytosine methylation and mammalian development", Genes and Development, vol. 13, no. 1, pp. 26-34, 1999.
40. G. Liang, M. F. Chan, Y. Tomigahara et al., "Cooper activity between DNA methyltransferases in the maintenance methylation of repetitive elements", Molecular and Cellular Biology, vol. 22, no. 2, pp. 480-491, 2002.
41. R. Straussman, D. Nejman, D. Roberts et al., "Developmental programming of CpG island methylation profles in the human genome", Nature Structural and Molecular Biology, vol. 16, no. 5, pp. 564-571, 2009.
42. S. Fan and X. Zhang, "CpG island methylation pattern in different human tissues and its correlation with gene expression", Biochemical and Biophysical Research Communications, vol. 383, no. 4, pp. 421-425, 2009.
43. K. T. Williams, T. A. Garrow, and K. L. Schalinske, "Type I diabetes leads to tissue-specific DNA hypomethylation in male rats", Journal of Nutrition, vol. 138, no. 11, pp. 2064-2069, 2008.
44. S. Thewari, Q. Zhong, J. M. Santos, and R. A. Kowluru, "Mitochondria DNA replication and DNA methylation in the metabolic memory associated with continued progression of diabetic retinopathy", Investigative Ophthalmology & Visual Science, vol. 53, no. 8, pp. 4881-4888, 2012.
45. C. G. Bell, A. E. Teschendorf, V. K. Rakyan, A. P. Maxwell, S. Beck, and D. A. Savage, "Genome-wide DNA methylation analysis for diabetic nephropathy in type 1 diabetes mellitus", BMC Medical Genomics, vol. 3, article 33, 2010.
46. F. Miao, Z. Chen, S. Genuth et al., "Evaluating the role of epigenetic histone modifications in the metabolic memory of type 1 diabetes", Diabetes, vol. 63, no. 5, pp. 1748-1762, 2014.
47. J. Krol, I. Loedige, and W. Filipowicz, "The widespread regulation of microRNA biogenesis, function and decay", Nature Reviews Genetics, vol. 11, no. 9, pp. 597-610, 2010.
48. C. Urbich, A. Kuehbacher, and S. Dimmeler, "Role of microRNAs in vascular diseases, infammation, and angiogenesis", Cardiovascular Research, vol. 79, no. 4, pp. 581-588, 2008.
49. W. Filipowicz, S. N. Bhattacharyya, and N. Sonenberg, "Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?" Nature Reviews Genetics, vol. 9, no. 2, pp. 102-114, 2008.
50. Y. Liang, D. Ridzon, L. Wong, and C. Chen, "Characterization of microRNA expression profles in normal human tissues", BMC Genomics, vol. 8, article 166, 2007.
51. I. Alvarez-Garcia and E. A. Miska, "MicroRNA functions in animal development and human disease", Development, vol. 132, no. 21, pp. 4653-4662, 2005.
52. A. Ribeiro, C. Schoof, A. Izzotti, L. Pereira, and L. Vasques, "MicroRNAs: modulators of cell identity, and their applications in tissue engineering", MicroRNA, vol. 3, no. 1, pp. 45-53, 2014.
53. M. R. Fabian, N. Sonenberg, and W. Filipowicz, "Regulation of mRNA translation and stability by microRNAs", Annual Review of Biochemistry, vol. 79, pp. 351-379, 2010.
54. M. Kato, N. E. Castro, and R. Natarajan, "MicroRNAs: potential mediators and biomarkers of diabetic complications", Free Radical Biology and Medicine, vol. 64, pp. 85-94, 2013.
55. M. Kato and R. Natarajan, "Diabetic nephropathy-emerging epigenetic mechanisms", Nature Reviews Nephrology, vol. 10, no. 9, pp. 517-530, 2014.
56. Y. Fu, Y. Zhang, Z. Wang et al., "Regulation of NADPH oxidase activity is associated with miRNA-25-mediated NOX4 expression in experimental diabetic nephropathy", The American Journal of Nephrology, vol. 32, no. 6, pp. 581-589, 2010.
57. Z. Zhang, H. Peng, J. Chen et al., "MicroRNA-21 protects from mesangial cell proliferation induced by diabetic nephropathy in db/db mice", FEBS Letters, vol. 583, no. 12, pp. 2009-2014, 2009.
58. B. Wang, P. Koh, C. Winbanks et al., "miR-200a prevents renal fibrogenesis through repression of TGF-β2 expression", Diabetes, vol. 60, no. 1, pp. 280-287, 2011.
59. Q. Wang, Y. Wang, A. W. Minto et al., "MicroRNA-377 is upregulated and can lead to increased fibronectin production in diabetic nephropathy", The FASEB Journal, vol. 22, no. 12, pp. 4126-4135, 2008.
60. S. Putta, L. Lanting, G. Sun, G. Lawson, M. Kato, and R. Natarajan, "Inhibiting microRNA-192 ameliorates renal fibrosis in diabetic nephropathy", Journal of the American Society of Nephrology, vol. 23, no. 3, pp. 458-469, 2012.
61. B. Feng, S. Chen, K. McArthur et al., "miR-146a-mediated extracellular matrix protein production in chronic diabetes complications", Diabetes, vol. 60, no. 11, pp. 2975-2984, 2011.
62. S. Swierczynski, E. Klieser, R. Illig, B. Alinger-Scharinger, T. Kiesslich, and D. Neureiter, "Histone deacetylation meets miRNA: epigenetics and post-transcriptional regulation in cancer and chronic diseases", Expert Opinion on Biological Therapy, vol. 15, no. 5, pp. 651-664, 2015.
63. C. E. Winbanks, B. Wang, C. Beyer et al., "TGF-beta regulates miR-206 and miR-29 to control myogenic differentiation through regulation of HDAC4", The Journal of Biological Chemistry, vol. 286, no. 16, pp. 13805-13814, 2011.
64. C. L. Lin, P. H. Lee, Y. C. Hsu et al., "MicroRNA-29a promotion of nephrin acetylation ameliorates hyperglycemia-induced podocyte dysfunction", Journal of the American Society of Nephrology, vol. 25, pp. 1698-1709, 2014.
65. Z.-X. Shan, Q.-X. Lin, C.-Y. Deng et al., "MiR-1/miR-206 regulate Hsp60 expression contributing to glucose-mediated apoptosis in cardiomyocytes", FEBS Letters, vol. 584, no. 16, pp. 3592-3600, 2010.
66. B. Feng, S. Chen, B. George, Q. Feng, and S. Chakrabarti, "miR133a regulates cardiomyocyte hypertrophy in diabetes", Diabetes/Metabolism Research and Reviews, vol. 26, no. 1, pp. 40-49, 2010.
67. S. Meng, J.-T. Cao, B. Zhang, Q. Zhou, C.-X. Shen, and C.-Q. Wang, "Downregulation of microRNA-126 in endothelial progenitor cells from diabetes patients, impairs their functional properties, via target gene Spred-1", Journal of Molecular and Cellular Cardiology, vol. 53, no. 1, pp. 64-72, 2012.
68. X. H. Wang, R. Z. Qian, W. Zhang, S. F. Chen, H. M. Jin, and R. M. Hu, "MicroRNA-320 expression in myocardial microvascular endothelial cells and its relationship with insulin-like growth factor-1 in type 2 diabetic rats", Clinical and Experimental Pharmacology and Physiology, vol. 36, no. 2, pp. 181-188, 2009.
69. A. Magenta, S. Greco, C. Gaetano, and F. Martelli, "Oxidative stress and microRNAs in vascular diseases", International Journal of Molecular Sciences, vol. 14, no. 9, pp. 17319-17346, 2013.
70. G. Togliatto, A. Trombetta, P. Dentelli et al., "Unacylated ghrelin (UnAG) induces oxidative stress resistance in a glucose intolerance mouse model and peripheral artery disease by restoring endothelial cell miR-126 expression", Diabetes, vol. 64, no. 4, pp. 1370-1382, 2015.
71. R. Margueron and D. Reinberg, "Chromatin structure and the inheritance of epigenetic information", Nature Reviews Genetics, vol. 11, no. 4, pp. 285-296, 2010.
72. C. Alabert and A. Groth, "Chromatin replication and epigenome maintenance", Nature Reviews Molecular Cell Biology, vol. 13, no. 3, pp. 153-167, 2012.
73. R. L. Jirtle and M. K. Skinner, "Environmental epigenomics and disease susceptibility", Nature Reviews Genetics, vol. 8, no. 4, pp. 253-262, 2007.
74. N. Grarup, C. H. Sandholt, T. Hansen, and O. Pedersen, "Genetic susceptibility to type 2 diabetes and obesity: from genome-wide association studies to rare variants and beyond", Diabetologia, vol. 57, pp. 1528-1541, 2014.
75. E. E. Ntzani and F. K. Kavvoura, "Genetic risk factors for type 2 diabetes: insights from the emerging genomic evidence", Current Vascular Pharmacology, vol. 10, no. 2, pp. 147-155, 2012.
76. R. Lister, M. Pelizzola, R. H. Dowen et al., "Human DNA methylomes at base resolution show widespread epigenomic diferences", Nature, vol. 462, no. 7271, pp. 315-322, 2009.
77. R. Bhandare, J. Schug, J. Le Lay et al., "Genome-wide analysis of histone modifications in human pancreatic islets", Genome Research, vol. 20, no. 4, pp. 428-433, 2010.
78. E. Nilsson, P. A. Jansson, A. Perfilyev et al., "Altered DNA methylation and differential expression of genes influencing metabolism and infammation in adipose tissue from subjects with type 2 diabetes", Diabetes, vol. 63, no. 9, pp. 2962-2976, 2014.
79. P. Yi, S. Melnyk, M. Pogribna, I. P. Pogribny, R. J. Hine, and S. J. James, "Increase in plasma homocysteine associated with parallel increases in plasma S-adenosylhomocysteine and lymphocyte DNA hypomethylation", The Journal of Biological Chemistry, vol. 275, no. 38, pp. 29318-29323, 2000.
80. C.-S. Kim, Y.-R. Kim, A. Naqvi et al., "Homocysteine promotes human endothelial cell dysfunction via site-specific epigenetic regulation of p66shc", Cardiovascular Research, vol. 92, no. 3, pp. 466-475, 2011.
81. D. M. Breen, V. W. Dolinsky, H. Zhang et al., "Resveratrol inhibits neointimal formation after arterial injury through an endothelial nitric oxide synthase-dependent mechanism", Atherosclerosis, vol. 222, no. 2, pp. 375-381, 2012.
82. M. M. Poulsen, P. F. Vestergaard, B. F. Clasen et al., "Highdose resveratrol supplementation in obese men: an investigatorinitiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition", Diabetes, vol. 62, no. 4, pp. 1186-1195, 2013.
83. M. A. El-Moselhy, A. Taye, S. S. Sharkawi, S. F. I. El-Sisi, and A. F. Ahmed, "The antihyperglycemic effect of curcumin in high fat diet fed rats. Role of TNF-α and free fatty acids", Food and Chemical Toxicology, vol. 49, no. 5, pp. 1129-1140, 2011.
84. C. A. Hamm and F. F. Costa, "The impact of epigenomics on future drug design and new therapies", Drug Discovery Today, vol. 16, no. 13-14, pp. 626-635, 2011.